Lin Chang-Ching相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer.

肿瘤微环境中的 CD8+ T 细胞调节乳腺癌对内分泌治疗的反应。

期刊:Journal of Clinical Investigation

影响因子:13.6

doi:10.1172/JCI188458

Napolitano Fabiana, Wang Yunguan, Sudhan Dhivya R, Gonzalez-Ericsson Paula I, Formisano Luigi, Unni Nisha, Shakeel Shahbano, Zhu James Z, Ahuja Khushi, Guo Lei, Chica-Parrado MarÃa Rosario, Matsunaga Yuki, Luna Pamela, Lin Chang-Ching A, Uemoto Yasuaki, Lee Kyung-Min, Ma Hongli, Evans Nathaniel J, Servetto Alberto, Mendiratta Saurabh, Barnes Spencer D, Bianco Roberto, Fang Yisheng V, Xu Lin, Lee Jeon, Wang Tao, Balko Justin M, Mills Gordon B, Labrie Marilyne, Hanker Ariella B, Arteaga Carlos L

细胞生物学

肿瘤微环境

发表日期：2026

文献求助收藏

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.

从临床到实验室的转化分析：激素受体阳性转移性乳腺癌中 NF1 改变和 CDK4/6 抑制剂耐药性

期刊:EBioMedicine

影响因子:10.8

doi:10.1016/j.ebiom.2025.105828

Lloyd Maxwell R, Chica-Parrado Rosario, Weipert Caroline M, Knepper Todd C, Podany Emily L, Napolitano Fabiana, Ye Dan, Lin Chang-Ching, Uemoto Yasuaki, Liao Jiemin, Wegrzyn Claire, Walko Christine M, Ryan Lianne Y, Keenan Jennifer C, Medford Arielle J, Liu Shiyuan A, Wulf Gerburg M, Clifton Katherine K, Ma Cynthia X, Han Hyo S, Zhang Nicole, Ellisen Leif W, Bardia Aditya, Arteaga Carlos L, Hanker Ariella B, Wander Seth A

发表日期：2025

文献求助收藏

ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.

ESR1 Y537S 和 D538G 突变导致雌激素受体阳性乳腺癌对 CDK4/6 抑制剂产生耐药性

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-24-2307

Lin Chang-Ching A, Chica-Parrado MarÃa Rosario, Unni Nisha, Jaeger Ellen, Fang Yisheng V, Guo Lei, Napolitano Fabiana, Luna Pamela, Harris Michelle, Chao Calvin, Xu Lin, Arteaga Carlos L, Hanker Ariella B

发表日期：2025

文献求助收藏

Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.

选择性降解 FGFR1/2 可克服 FGFR1/2 改变的 ER+ 乳腺癌的抗雌激素耐药性

期刊:Cancer Letters

影响因子:10.1

doi:10.1016/j.canlet.2025.217668

Uemoto Yasuaki, Lin Chang-Ching A, Wang Bingnan, Ye Dan, Fang Yisheng V, Bikorimana Emmanuel, Napolitano Fabiana, Chica-Parrado Maria Rosario, Li Cheung, Mendiratta Saurabh, Chen Chuo, Hanker Ariella B, Arteaga Carlos L

发表日期：2025

文献求助收藏

Why does AI hinder democratization?

为什么人工智能会阻碍民主化进程？

期刊:Proceedings of the National Academy of Sciences of the United States of America

影响因子:9.1

doi:10.1073/pnas.2423266122

Chu, C Y Cyrus; Chang, Juin-Jen; Lin, Chang-Ching

发表日期：2025

文献求助收藏

Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions

血清IL-6和PTX3水平可预测门诊COVID-19患者的重症预后：对未来治疗决策的影响

期刊:PLoS One

影响因子:2.6

doi:10.1371/journal.pone.0324242

Poorbaugh, Josh; Sims, Jonathan T; Zhang, Lin; Chang, Ching-Yun; Higgs, Richard E; Nirula, Ajay; Benschop, Robert J

发表日期：2025

文献求助收藏

The influences of antihistamine on liver fibrosis, vasoresponsiveness, and portosystemic shunting in bile duct-ligated cirrhotic rats.

抗组胺药对胆管结扎肝硬化大鼠肝纤维化、血管反应性和门体分流的影响。

期刊:Journal of the Chinese Medical Association

影响因子:2.4

doi:10.1097/JCMA.0000000000001301

Chang Chien-Lin, Chang Ching-Chih, Chuang Chiao-Lin, Hsu Shao-Jung, Tsai Ming-Hung, Tsai Chia-Jui, Chang Yu-Yin, Hou Ming-Chih, Lee Fa-Yauh

发表日期：2025

文献求助收藏

Parental mixed-gender preferences revealed by IVF twin births

试管婴儿双胞胎的出生揭示了父母对异性生育的偏好

期刊:Proceedings of the National Academy of Sciences of the United States of America

doi:10.1073/pnas.2426838122

Chu, C Y Cyrus; Lin, Chang-Ching; Lu, Shih-Ting; Kao, Ching-Yuan

发表日期：2025

文献求助收藏

Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.

CDK4/6 和 AKT 的联合抑制对三阴性乳腺癌的管腔雄激素受体 (LAR) 亚型具有高度疗效

期刊:Cancer Letters

影响因子:10.1

doi:10.1016/j.canlet.2024.217219

Chica-Parrado MarÃa Rosario, Kim Gun Min, Uemoto Yasuaki, Napolitano Fabiana, Lin Chang-Ching, Ye Dan, Bikorimana Emmanuel, Fang Yisheng, Lee Kyung-Min, Mendiratta Saurabh, Hanker Ariella B, Arteaga Carlos L

发表日期：2024

文献求助收藏

Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

蛋白质精氨酸甲基转移酶5 (PRMT5) 是 CDK4/6 抑制剂耐药的 ER+/RB 缺陷型乳腺癌中一个可靶向的治疗靶点。

doi:10.21203/rs.3.rs-2966905/v1

Lin, Chang-Ching; Chang, Tsung-Cheng; Wang, Yunguan; Guo, Lei; Gao, Yunpeng; Bikorimana, Emmanuel; Lemoff, Andrew; Fang, Yisheng V; Zhang, He; Zhang, Yanfeng; Ye, Dan; Soria-Bretones, Isabel; Servetto, Alberto; Lee, Kyung-Min; Luo, Xuemei; Otto, Joseph J; Akamatsu, Hiroaki; Napolitano, Fabiana; Mani, Ram; Cescon, David W; Xu, Lin; Xie, Yang; Mendell, Joshua T; Hanker, Ariella B; Arteaga, Carlos L

发表日期：2023

文献求助收藏